U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Bolen S, Wilson L, Vassy J, et al. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jul. (Comparative Effectiveness Reviews, No. 8.)

Cover
Cover of Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes

Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes [Internet].

Show details

References

1.
Harris MI , Flegal KM , Cowie CC . et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21(4):518–24. [PubMed: 9571335]
2.
Mokdad AH , Ford ES , Bowman BA . et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23(9):1278–83. [PubMed: 10977060]
3.
National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Fact Sheet. [Web Page]. (Accessed 6 July 1906).
4.
National Center for Chronic Disease Prevention and Health Promotion. Data & Trends: National Diabetes Surveillance System. [Web Page]. 1998; (Accessed 6 July 1906).
5.
Schellhase KG , Koepsell TD , Weiss NS . Glycemic control and the risk of multiple microvascular diabetic complications. Fam Med. 2005;37(2):125–30. [PubMed: 15690253]
6.
Vijan S , Hofer TP , Hayward RA . Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127(9):788–95. [PubMed: 9382399]
7.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837–53. [PubMed: 9742976]
8.
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44(8):968–83. [PubMed: 7622004]
9.
Selvin E , Marinopoulos S , Berkenblit G . et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–31. [PubMed: 15381515]
10.
Garratt KN , Brady PA , Hassinger NL , Grill DE , Terzic A , Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33(1):119–24. [PubMed: 9935017]
11.
Lomuscio A , Fiorentini C . Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Diabetes Res Clin Pract. 1996;31(Suppl):S21–6. [PubMed: 8864637]
12.
Johnson JA , Majumdar SR , Simpson SH , Toth EL . Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25(12):2244–8. [PubMed: 12453968]
13.
Johnson JA , Simpson SH , Toth EL , Majumdar SR . Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med. 2005;22(4):497–502. [PubMed: 15787679]
14.
Simpson SH , Majumdar SR , Tsuyuki RT , Eurich DT , Johnson JA . Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006;174(2):169–74. [PMC free article: PMC1329454] [PubMed: 16415461]
15.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):854–65. [PubMed: 9742977]
16.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837–53. [PubMed: 9742976]
17.
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; (3):CD002966. [PubMed: 16034881]
18.
Chilcott J , Tappenden P , Jones ML , Wight JP . A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23(11):1792–823. discussion 1791. [PubMed: 11768834]
19.
Chandler, C, Chou, R, Helfand, M. Drug Class Review on Oral Hypoglycemics [Web Page]. May 2005; Available at http://www​.ohsu.edu/drugeffectiveness​/reports​/documents/OH%20Final​%20Report%20Update%2021.pdf. (Accessed 10 January 2006).
20.
Chiquette E , Ramirez G , Defronzo R . A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164(19):2097–104. [PubMed: 15505122]
21.
van de Laar FA , Lucassen PL , Akkermans RP , van de Lisdonk EH , Rutten GE , van Weel C . Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28(1):154–63. [PubMed: 15616251]
22.
Wulffele MG , Kooy A , de Zeeuw D , Stehouwer CD , Gansevoort RT . The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256(1):1–14. [PubMed: 15189360]
23.
van Wijk JP , de Koning EJ , Martens EP , Rabelink TJ . Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23(10):1744–9. [PubMed: 12907465]
24.
Inzucchi SE . Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–72. [PubMed: 11790216]
25.
Buse JB , Tan MH , Prince MJ , Erickson PP . The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6(2):133–56. [PubMed: 14746579]
26.
Bristol-Myers Squibb Company. Patient Information: Glucophage and Glucophage XR [Web Page]. 22 October 2006;
27.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317(7160):703–13. [PMC free article: PMC28659] [PubMed: 9732337]
28.
KANNEL WB , DAWBER TR , FRIEDMAN GD , GLENNON WE , MCNAMARA PM . RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY. Ann Intern Med. 1964;61:888–99. [PubMed: 14233810]
29.
Clinical Practice Recommendations 2005. Diabetes Care 2005; 28 Suppl 1:S1–79. [PubMed: 15618109]
30.
Manley S . Haemoglobin A1c—a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med. 2003;41(9):1182–90. [PubMed: 14598868]
31.
The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management—2000 update. Endocr Pract 2000; 6(1):43–84. [PubMed: 11428359]
32.
Ceriello A , Davidson J , Hanefeld M . et al. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis. 2006;16(7):453–6. [PubMed: 16934443]
33.
Kasper DL, Braunwald E, Fauci AS, et al, Eds. Harrison's Principles of Internal Medicine, 16th Edition. New York: McGraw-Hill, Medical Pub. Division; 2005.
34.
Schroeder K , Fahey T , Ebrahim S . How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164(7):722–32. [PubMed: 15078641]
35.
Available at: UpToDate. http://www​.uptodate.com. (Accessed September 2006).
36.
Available at: drugstore​.com Online pharmacy. (Accessed September 2006).
37.
Berlin JA . Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350(9072):185–6. [PubMed: 9250191]
38.
Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; (2):CD003639. [PMC free article: PMC8406605] [PubMed: 15846673]
39.
Kimmel B , Inzucchi SE . Oral agents for type 2 diabetes: An update. Clin Diabetes. 2005;23(2):64–76.
40.
Jadad AR , Moore RA , Carroll D . et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. [PubMed: 8721797]
41.
Moher D , Cook DJ , Eastwood S , Olkin I , Rennie D , Stroup DF . Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896–900. [PubMed: 10584742]
42.
Deeks JJ, Dinnes J, D'Amico R et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7(27):iii–x, 1–173. [PubMed: 14499048]
43.
DerSimonian R , Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. [PubMed: 3802833]
44.
Higgins JP , Thompson SG , Deeks JJ , Altman DG . Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
45.
Song F , Altman DG , Glenny AM , Deeks JJ . Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472. [PMC free article: PMC150178] [PubMed: 12609941]
46.
Begg CB , Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101. [PubMed: 7786990]
47.
Egger M , Davey Smith G , Schneider M , Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
48.
Atkins D , Best D , Briss PA . et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. [PMC free article: PMC428525] [PubMed: 15205295]
49.
Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2003; (2):CD002967. [PubMed: 12804446]
50.
Saydah SH , Eberhardt MS , Loria CM , Brancati FL . Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol. 2002;156(8):714–9. [PubMed: 12370159]
51.
Khan MA , St Pete JV , Xue JL . A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25(4):708–11. [PubMed: 11919129]
52.
Goldberg RB , Kendall DM , Deeg MA . et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547–54. [PubMed: 15983299]
53.
Derosa G , Cicero AF , Gaddi A . et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005;69(1):5–13. [PubMed: 15955382]
54.
Lawrence JM , Reid J , Taylor GJ , Stirling C , Reckless JP . Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care. 2004;27(1):41–6. [PubMed: 14693964]
55.
Ramachandran A , Snehalatha C , Salini J , Vijay V . Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes—a study in Indians. J Assoc Physicians India. 2004;52:459–63. [PubMed: 15645955]
56.
Schernthaner G , Matthews DR , Charbonnel B , Hanefeld M , Brunetti P . Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89(12):6068–76. [PubMed: 15579760]
57.
Yamanouchi T , Sakai T , Igarashi K , Ichiyanagi K , Watanabe H , Kawasaki T . Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005;22(8):980–5. [PubMed: 16026361]
58.
Hallsten K , Virtanen KA , Lonnqvist F . et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002;51(12):3479–85. [PubMed: 12453903]
59.
Pavo I , Jermendy G , Varkonyi TT . et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(4):1637–45. [PubMed: 12679450]
60.
Hanefeld M , Brunetti P , Schernthaner GH , Matthews DR , Charbonnel BH . One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141–7. [PubMed: 14693980]
61.
Tan MH , Baksi A , Krahulec B . et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28(3):544–50. [PubMed: 15735185]
62.
Yanagawa T , Araki A , Sasamoto K , Shirabe S , Yamanouchi T . Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism. 2004;53(3):353–7. [PubMed: 15015149]
63.
Charbonnel BH , Matthews DR , Schernthaner G , Hanefeld M , Brunetti P . A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22(4):399–405. [PubMed: 15787663]
64.
Nakamura T , Ushiyama C , Shimada N , Hayashi K , Ebihara I , Koide H . Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14(5):250–4. [PubMed: 11113686]
65.
Tan MH , Johns D , Strand J . et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med. 2004;21(8):859–66. [PubMed: 15270789]
66.
Bakris G , Viberti G , Weston WM , Heise M , Porter LE , Freed MI . Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17(1):7–12. [PubMed: 12571611]
67.
St John Sutto M , Rendell M , Dandona P . et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058–64. [PubMed: 12401757]
68.
Pfutzner A , Marx N , Lubben G . et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925–31. [PubMed: 15963388]
69.
Tan M , Johns D , Gonzalez Galvez G . et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 2004;26(5):680–93. [PubMed: 15220012]
70.
Matthews DR , Charbonnel BH , Hanefeld M , Brunetti P , Schernthaner G . Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167–74. [PubMed: 15386821]
71.
Garber A , Klein E , Bruce S , Sankoh S , Mohideen P . Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2006;8(2):156–63. [PubMed: 16448519]
72.
Derosa G , Gaddi AV , Ciccarelli L . et al. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J Int Med Res. 2005;33(3):284–94. [PubMed: 15938589]
73.
Jovanovic L , Hassman DR , Gooch B . et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract. 2004;63(2):127–34. [PubMed: 14739053]
74.
Raskin P , McGill J , Saad MF . et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med. 2004;21(4):329–35. [PubMed: 15049934]
75.
Goke B . Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol. 2002;1(5):329–36. [PubMed: 15832486]
76.
McCluskey D , Touger MS , Melis R , Schleusener DS , McCluskey D . Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Ther. 2004;26(11):1783–90. [PubMed: 15639690]
77.
Choi D , Kim SK , Choi SH . et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27(11):2654–60. [PubMed: 15505001]
78.
Takagi T , Yamamuro A , Tamita K . et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003;146(2):E5. [PubMed: 12891212]
79.
Garber AJ , Larsen J , Schneider SH , Piper BA , Henry D . Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4(3):201–8. [PubMed: 12047399]
80.
Garber AJ , Donovan DS Jr, Dandona P , Bruce S , Park JS . Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003;88(8):3598–604. [PubMed: 12915642]
81.
Blonde L , Rosenstock J , Mooradian AD , Piper BA , Henry D . Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab. 2002;4(6):368–75. [PubMed: 12406033]
82.
Goldstein BJ , Pans M , Rubin CJ . Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther. 2003;25(3):890–903. [PubMed: 12852706]
83.
Campbell IW , Menzies DG , Chalmers J , McBain AM , Brown IR . One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab. 1994;20(4):394–400. [PubMed: 7843470]
84.
Marre M , Howlett H , Lehert P , Allavoine T . Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673–80. [PubMed: 12147149]
85.
Amador-Licona N , Guizar-Mendoza J , Vargas E , Sanchez-Camargo G , Zamora-Mata L . The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res. 2000;31(6):571–5. [PubMed: 11257323]
86.
Noury J , Nandeuil A . Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab. 1991;17(1 Pt 2):209–12. [PubMed: 1936478]
87.
Hermann LS , Schersten B , Bitzen PO , Kjellstrom T , Lindgarde F , Melander A . Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17(10):1100–9. [PubMed: 7821128]
88.
DeFronzo RA , Goodman AM . Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–9. [PubMed: 7623902]
89.
Charpentier G , Fleury F , Kabir M , Vaur L , Halimi S . Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001;18(10):828–34. [PubMed: 11678974]
90.
Derosa G , Franzetti I , Gadaleta G , Ciccarelli L , Fogari R . Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab. 2004;17(3):143–50. [PubMed: 15334791]
91.
U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study. Diabetes 1985; 34(8):793–8. [PubMed: 2862087]
92.
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310(6972):83–8. [PMC free article: PMC2548496] [PubMed: 7833731]
93.
Turner R , Murchison L , Wright AD . et al. United Kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128(3):165–75. [PubMed: 9454524]
94.
Hermann LS , Bitzen PO , Kjellstrom T , Lindgarde F , Schersten B . Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. Diabete Metab. 1991;17(1 Pt 2):201–8. [PubMed: 1936477]
95.
Tosi F , Muggeo M , Brun E . et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003;52(7):862–7. [PubMed: 12870162]
96.
Horton ES , Clinkingbeard C , Gatlin M , Foley J , Mallows S , Shen S . Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660–5. [PubMed: 11092289]
97.
Derosa G , Mugellini A , Ciccarelli L , Crescenzi G , Fogari R . Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract. 2003;60(3):161–9. [PubMed: 12757988]
98.
Wolever TMS , Assiff L , Basu T . et al. Miglitol, an (alpha)-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Nutr Res. 2000;20(10):1447–56.
99.
Willms B , Ruge D . Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med. 1999;16(9):755–61. [PubMed: 10510952]
100.
Weissman P , Goldstein BJ , Rosenstock J . et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin. 2005;21(12):2029–35. [PubMed: 16368054]
101.
Bailey CJ , Bagdonas A , Rubes J . et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005;27(10):1548–61. [PubMed: 16330291]
102.
Gomez-Perez FJ , Fanghanel-Salmon G , Antonio Barbosa J . et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002;18(2):127–34. [PubMed: 11994904]
103.
Fonseca V , Rosenstock J , Patwardhan R , Salzman A . Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695–702. [PubMed: 10755495]
104.
Feinglos M , Dailey G , Cefalu W . et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract. 2005;68(2):167–75. [PubMed: 15860246]
105.
Fujioka K , Pans M , Joyal S . Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25(2):515–29. [PubMed: 12749511]
106.
Schernthaner G , Grimaldi A , Di Mario U . et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535–42. [PubMed: 15305887]
107.
Dills DG , Schneider J . Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res. 1996;28(9):426–9. [PubMed: 8911977]
108.
Carlson RF , Isley WL , Ogrinc FG , Klobucar TR . Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther. 1993;15(5):788–96. [PubMed: 8269445]
109.
Rosenstock J , Corrao PJ , Goldberg RB , Kilo C . Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clin Ther. 1993;15(6):1031–40. [PubMed: 8111800]
110.
Birkeland KI , Furuseth K , Melander A , Mowinckel P , Vaaler S . Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. Diabetes Care. 1994;17(1):45–9. [PubMed: 8112188]
111.
Inukai K , Watanabe M , Nakashima Y . et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract. 2005;68(3):250–7. [PubMed: 15936468]
112.
Draeger KE , Wernicke-Panten K , Lomp HJ , Schuler E , Rosskamp R . Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res. 1996;28(9):419–25. [PubMed: 8911976]
113.
Harrower AD . Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin. 1985;9(10):676–80. [PubMed: 3935376]
114.
Kardas P . The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7(6):722–8. [PubMed: 16219016]
115.
Yamagishi S , Nakamura K , Inoue H . Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH). Med Hypotheses. 2005;65(2):377–9. [PubMed: 15922116]
116.
Marbury T , Huang WC , Strange P , Lebovitz H . Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract. 1999;43(3):155–66. [PubMed: 10369424]
117.
Wolffenbuttel BH , Landgraf R . A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care. 1999;22(3):463–7. [PubMed: 10097930]
118.
Derosa G , Mugellini A , Ciccarelli L , Crescenzi G , Fogari R . Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther. 2003;25(2):472–84. [PubMed: 12749508]
119.
Madsbad S , Kilhovd B , Lager I , Mustajoki P , Dejgaard A . Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med. 2001;18(5):395–401. [PubMed: 11472451]
120.
Wolffenbuttel BH , Nijst L , Sels JP , Menheere PP , Muller PG , Kruseman AC . Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol. 1993;45(2):113–6. [PubMed: 8223830]
121.
Landgraf R , Bilo HJ , Muller PG . A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol. 1999;55(3):165–71. [PubMed: 10379630]
122.
Vakkilainen J , Mero N , Schweizer A , Foley JE , Taskinen MR . Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev. 2002;18(6):484–90. [PubMed: 12469362]
123.
Pfutzner A , Schondorf T , Seidel D . et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism. 2006;55(1):20–5. [PubMed: 16324915]
124.
Rosenstock J , Goldstein BJ , Vinik AI . et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab. 2006;8(1):49–57. [PubMed: 16367882]
125.
Kerenyi Z , Samer H , James R , Yan Y , Stewart M . Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2004;63(3):213–23. [PubMed: 14757293]
126.
Baksi A , James RE , Zhou B , Nolan JJ . Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol. 2004;41(2):63–9. [PubMed: 15224207]
127.
Erle G , Lovise S , Stocchiero C . et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetol. 1999;36(12):61–5. [PubMed: 10436254]
128.
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care 1998; 21(1):87–92. [PubMed: 9538975]
129.
Gregorio F , Ambrosi F , Manfrini S . et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med. 1999;16(12):1016–24. [PubMed: 10656230]
130.
Feinbock C , Luger A , Klingler A . et al. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab. 2003;16(4):214–21. [PubMed: 14768770]
131.
Rosenstock J , Hassman DR , Madder RD . et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27(6):1265–70. [PubMed: 15161773]
132.
Azriel R , Gazit E . Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J Biol Chem. 2001;276(36):34156–61. [PubMed: 11445568]
133.
Baba S , Nakagawa S , Takebe K . et al. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. Tohoku J Exp Med. 1983;141(Suppl):693–706. [PubMed: 6440313]
134.
Goldberg RB , Holvey SM , Schneider J . A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996;19(8):849–56. [PubMed: 8842603]
135.
Schade DS , Jovanovic L , Schneider J . A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol. 1998;38(7):636–41. [PubMed: 9702849]
136.
Simonson DC , Kourides IA , Feinglos M , Shamoon H , Fischette CT . Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care. 1997;20(4):597–606. [PubMed: 9096986]
137.
Vray M , Attali JR . Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes. Diabete Metab. 1995;21(6):433–9. [PubMed: 8593925]
138.
Hasche H , Mertes G , Bruns C . et al. Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab. 1999;12(4):277–85. [PubMed: 10782754]
139.
Goldberg RB , Einhorn D , Lucas CP . et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care. 1998;21(11):1897–903. [PubMed: 9802740]
140.
Tseng CH , Huang TS . Pioglitazone with sulfonylurea: Glycemic and lipid effects in Taiwanese type 2 diabetic patients. Diabetes Res Clin Pract. 2005;70(2):193–4. [PubMed: 16188579]
141.
Scherbaum WA , Goke B . Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res. 2002;34(10):589–95. [PubMed: 12439788]
142.
King AB . A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care. 2000;23(4):557. [PubMed: 10857952]
143.
Virtanen KA , Hallsten K , Parkkola R . et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 2003;52(2):283–90. [PubMed: 12540598]
144.
Natali A , Baldeweg S , Toschi E . et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27(6):1349–57. [PubMed: 15161787]
145.
Forst T , Lubben G , Hohberg C . et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation. 2005;12(7):543–50. [PubMed: 16207627]
146.
Langenfeld MR , Forst T , Hohberg C . et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111(19):2525–31. [PubMed: 15883215]
147.
Kilo C . Multicenter comparison of glyburide and glipizide in the treatment of non-insulin-dependent diabetes mellitus. Clin Ther. 1988;10(3):294–302. [PubMed: 3152586]
148.
Manzella D , Grella R , Esposito K , Giugliano D , Barbagallo M , Paolisso G . Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens. 2004;17(3):223–7. [PubMed: 15001195]
149.
Del Prato S , Erkelens DW , Leutenegger M . Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol. 2003;40(1):20–7. [PubMed: 12682825]
150.
Rachmani R , Slavachevski I , Levi Z , Zadok B , Kedar Y , Ravid M . Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med. 2002;13(7):428. [PubMed: 12384131]
151.
Nishio K , Sakurai M , Kusuyama T . et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006;29(1):101–6. [PubMed: 16373904]
152.
Kim YM , Cha BS , Kim DJ . et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract. 2005;67(1):43–52. [PubMed: 15620433]
153.
Rosenbaum P , Peres RB , Zanella MT , Ferreira SRG . Improved glycemic control by acarbose therapy in hypertensive diabetic patients: Effects on blood pressure and hormonal parameters. Braz J Med Biol Res. 2002;35(8):877–84. [PubMed: 12185379]
154.
Grant PJ . The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19(1):64–6. [PubMed: 8720537]
155.
Teupe B , Bergis K . Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metab. 1991;17(1 Pt 2):213–7. [PubMed: 1936479]
156.
Derosa G , Cicero AF , Gaddi A . et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther. 2004;26(5):744–54. [PubMed: 15220018]
157.
Betteridge DJ , Verges B . Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia. 2005;48(12):2477–81. [PubMed: 16283239]
158.
Derosa G , Gaddi AV , Piccinni MN . et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab. 2006;8(2):197–205. [PubMed: 16448524]
159.
Hermann LS , Kjellstrom T , Nilsson-Ehle P . Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabete Metab. 1991;17(1 Pt 2):174–9. [PubMed: 1936472]
160.
Einhorn D , Rendell M , Rosenzweig J , Egan JW , Mathisen AL , Schneider RL . Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22(12):1395–409. [PubMed: 11192132]
161.
Smith SR , De Jonge L , Volaufova J , Li Y , Xie H , Bray GA . Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 2005;54(1):24–32. [PubMed: 15562376]
162.
Rosenblatt S , Miskin B , Glazer NB , Prince MJ , Robertson KE . The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12(5):413–23. [PubMed: 11491207]
163.
Herz M , Johns D , Reviriego J . et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther. 2003;25(4):1074–95. [PubMed: 12809958]
164.
Saad MF , Greco S , Osei K . et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 2004;27(6):1324–9. [PubMed: 15161783]
165.
Aronoff S , Rosenblatt S , Braithwaite S , Egan JW , Mathisen AL , Schneider RL . Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605–11. [PubMed: 11092281]
166.
Kipnes MS , Krosnick A , Rendell MS , Egan JW , Mathisen AL , Schneider RL . Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1):10–7. [PubMed: 11448655]
167.
Patel J , Anderson RJ , Rappaport EB . Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1(3):165–72. [PubMed: 11220295]
168.
Phillips LS , Grunberger G , Miller E , Patwardhan R , Rappaport EB , Salzman A . Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–15. [PubMed: 11213884]
169.
Lebovitz HE , Dole JF , Patwardhan R , Rappaport EB , Freed MI . Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280–8. [PubMed: 11232013]
170.
Vongthavaravat V , Wajchenberg BL , Waitman JN . et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin. 2002;18(8):456–61. [PubMed: 12564655]
171.
Wolffenbuttel BH , Gomis R , Squatrito S , Jones NP , Patwardhan RN . Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med. 2000;17(1):40–7. [PubMed: 10691158]
172.
Barnett AH , Grant PJ , Hitman GA . et al. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet Med. 2003;20(5):387–93. [PubMed: 12752488]
173.
Schneider J . Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. Diabete Metab. 1991;17(1 Pt 2):185–90. [PubMed: 1936474]
174.
Lexchin J , Bero LA , Djulbegovic B , Clark O . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70. [PMC free article: PMC156458] [PubMed: 12775614]
175.
Bucher HC , Guyatt GH , Griffith LE , Walter SD . The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91. [PubMed: 9250266]
176.
Cryer DR , Nicholas SP , Henry DH , Mills DJ , Stadel BV . Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care. 2005;28(3):539–43. [PubMed: 15735184]
177.
Gulliford M , Latinovic R . Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004;20(3):239–45. [PubMed: 15133756]
178.
Olsson J , Lindberg G , Gottsater M . et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000;43(5):558–60. [PubMed: 10855529]
179.
Eurich DT , Majumdar SR , McAlister FA , Tsuyuki RT , Johnson JA . Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–51. [PubMed: 16186261]
180.
Evans JM , Ogston SA , Emslie-Smith A , Morris AD . Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930–6. [PubMed: 16525843]
181.
Mannucci E , Monami M , Masotti G , Marchionni N . All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev. 2004;20(1):44–7. [PubMed: 14737744]
182.
Meier JJ , Deifuss S , Klamann A , Schmiegel W , Nauck MA . Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes. 2003;111(6):344–50. [PubMed: 14520601]
183.
Klamann A , Sarfert P , Launhardt V , Schulte G , Schmiegel WH , Nauck MA . Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J. 2000;21(3):220–9. [PubMed: 10639304]
184.
Inzucchi SE , Masoudi FA , Wang Y . et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: Insights from the national heart care project. Diabetes Care. 2005;28(7):1680–9. [PubMed: 15983320]
185.
Dormandy JA , Charbonnel B , Eckland DJ . et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89. [PubMed: 16214598]
186.
Fisman EZ , Tenenbaum A , Boyko V . et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol. 2001;24(2):151–8. [PMC free article: PMC6655246] [PubMed: 11460818]
187.
Florkowski CM , Scott RS , Coope PA , Moir CL . Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. Diabetes Res Clin Pract. 2001;53(2):113–20. [PubMed: 11403860]
188.
Zhu XX , Pan CY , Li GW . et al. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther. 2003;5(1):33–42. [PubMed: 12725705]
189.
Rosenstock J , Samols E , Muchmore DB , Schneider J . Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care. 1996;19(11):1194–9. [PubMed: 8908379]
190.
Hanefeld M , Bouter KP , Dickinson S , Guitard C . Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000;23(2):202–7. [PubMed: 10868832]
191.
Sonnenberg GE , Garg DC , Weidler DJ . et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1997;31(6):671–6. [PubMed: 9184703]
192.
Gegick CG , Altheimer MD . Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract. 2001;7(3):162–9. [PubMed: 11421562]
193.
Luis Bautista J , Bugos C , Dirnberger G , Atherton T . Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2003;25(1):194–209. [PubMed: 12637120]
194.
Jovanovic L , Dailey G 3rd, Huang WC , Strange P , Goldstein BJ . Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol. 2000;40(1):49–57. [PubMed: 10631622]
195.
Ikeda T . QT prolongation in type 2 diabetes mellitus treated with glibenclamide. Diabete Metab. 1994;20(6):565–7. [PubMed: 7713283]
196.
Akanuma Y , Kosaka K , Kanazawa Y , Kasuga M , Fukuda M , Aoki S . Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. Diabetes Res Clin Pract. 1988;5(2):81–90. [PubMed: 3416710]
197.
Bech P , Moses R , Gomis R . The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naive Type 2 diabetes: a placebo-controlled, multicentre study. Qual Life Res. 2003;12(4):413–25. [PubMed: 12797714]
198.
Testa MA , Simonson DC . Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280(17):1490–6. [PubMed: 9809729]
199.
Papa G , Fedele V , Rizzo MR . et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: a randomized, open-label, two-period, cross-over trial. Diabetes Care. 2006;29(8):1918–20. [PubMed: 16873803]
200.
Frenchman IB . Treatment and treatment-related adverse events of type 2 diabetes mellitus in residents of long-term care facilities: A retrospective study. Curr Ther Res Clin Exp. 2003;64(1):1–9. [PMC free article: PMC4053022] [PubMed: 24944352]
201.
Leese GP , Wang J , Broomhall J . et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26(4):1176–80. [PubMed: 12663593]
202.
Holstein A , Plaschke A , Egberts EH . Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17(6):467–73. [PubMed: 11757083]
203.
Jennings AM , Wilson RM , Ward JD . Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989;12(3):203–8. [PubMed: 2702912]
204.
van Staa T , Abenhaim L , Monette J . Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50(6):735–41. [PubMed: 9250272]
205.
Shorr RI , Ray WA , Daugherty JR , Griffin MR . Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751–5. [PubMed: 8675920]
206.
Charpentier G , Vaur L , Halimi S . et al. Predictors of response to glimepiride in patients with type 2 diabetes mellitus. Diabetes Metab. 2001;27(5 Pt 1):563–71. [PubMed: 11694855]
207.
Rosenstock J , Meisel A , Raskin P . Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus. Am J Med. 1987;83(3A):10–5. [PubMed: 3307402]
208.
Bell DS , Yumuk V . Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Pract. 1997;3(5):281–3. [PubMed: 15251781]
209.
Cathelineau G , de Champvallins M , Bouallouche A , Lesobre B . Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment—the Diadem Study. Metabolism. 1997;46(12 Suppl 1):31–4. [PubMed: 9439556]
210.
Swislocki AL , Khuu Q , Liao E . et al. Safety and efficacy of metformin in a restricted formulary. Am J Manag Care. 1999;5(1):62–8. [PubMed: 10345968]
211.
Haupt E , Knick B , Koschinsky T , Liebermeister H , Schneider J , Hirche H . Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab. 1991;17(1 Pt 2):224–31. [PubMed: 1936481]
212.
Chandrasekharan S , Rao PP , Jayaram S , Jain SD , Ganesan R , Desai A . Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus. J Indian Med Assoc. 2002;100(7):467–8. [PubMed: 12674176]
213.
Mertes G . Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract. 2001;52(3):193–204. [PubMed: 11323089]
214.
Bhansali A , Masoodi SR . Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus. J Assoc Physicians India. 2005;53:441–5. [PubMed: 16124352]
215.
Dandona P , Fonseca V , Mier A , Beckett AG . Diarrhea and metformin in a diabetic clinic. Diabetes Care. 1983;6(5):472–4. [PubMed: 6336343]
216.
Bytzer P , Talley NJ , Jones MP , Horowitz M . Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15(1):137–42. [PubMed: 11136287]
217.
Garber AJ , Duncan TG , Goodman AM , Mills DJ , Rohlf JL . Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–7. [PubMed: 9428832]
218.
Moses RG , Gomis R , Frandsen KB , Schlienger JL , Dedov I . Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care. 2001;24(1):11–5. [PubMed: 11194214]
219.
Kane MP , Busch RS , Bakst G , Hamilton RA . Substitution of pioglitazone for troglitazone in patients with type 2 diabetes. Endocr Pract. 2004;10(1):18–23. [PubMed: 15251617]
220.
Lysy J , Israeli E , Goldin E . The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94(8):2165–70. [PubMed: 10445544]
221.
Gregorio F , Ambrosi F , Filipponi P , Manfrini S , Testa I . Is metformin safe enough for ageing type 2 diabetic patients? Diabetes Metab. 1996;22(1):43–50. [PubMed: 8697295]
222.
Chalasani N , Teal E , Hall SD . Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol. 2005;100(6):1317–21. [PubMed: 15929763]
223.
Rajagopalan R , Iyer S , Khan M . Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin. 2005;21(1):163–72. [PubMed: 15881488]
224.
Chan KA , Truman A , Gurwitz JH . et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003;163(6):728–34. [PubMed: 12639207]
225.
Kubo K . Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J. 2002;49(3):323–8. [PubMed: 12201216]
226.
Schofl C , Lubben G . Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice. Clin Drug Invest. 2003;23(11):725–34. [PubMed: 17536886]
227.
Ballary C, Desai A. Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus—a postmarketing study. J Indian Med Assoc 2003; 101(2):113–4, 123. [PubMed: 12841496]
228.
Delea TE , Edelsberg JS , Hagiwara M , Oster G , Phillips LS . Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26(11):2983–9. [PubMed: 14578227]
229.
Masoudi FA , Inzucchi SE , Wang Y , Havranek EP , Foody JM , Krumholz HM . Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111(5):583–90. [PubMed: 15699279]
230.
Nichols GA , Koro CE , Gullion CM , Ephross SA , Brown JB . The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005;21(1):51–7. [PubMed: 15386819]
231.
Hartung DM , Touchette DR , Bultemeier NC , Haxby DG . Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy. 2005;25(10):1329–36. [PubMed: 16185176]
232.
Maru S , Koch GG , Stender M . et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care. 2005;28(1):20–6. [PubMed: 15616228]
233.
Jun JK , Gong WC , Mathur R . Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Am J Health Syst Pharm. 2003;60(5):469–73. [PubMed: 12635453]
234.
Kahara T , Takamura T , Misaki T . et al. Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. Endocr J. 2005;52(3):373–6. [PubMed: 16006733]
235.
Stang M , Wysowski DK , Butler-Jones D . Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22(6):925–7. [PubMed: 10372243]
236.
Aguilar C , Reza A , Garcia JE , Rull JA . Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res. 1992;23(1):19–24. [PubMed: 1308787]
237.
Selby JV , Ettinger B , Swain BE , Brown JB . First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care. 1999;22(1):38–44. [PubMed: 10333901]
238.
Wiholm BE , Myrhed M . Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol. 1993;44(6):589–91. [PubMed: 8405019]
239.
Manley HJ , Allcock NM . Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy. 2003;23(7):861–5. [PubMed: 12885099]
240.
Bowker SL , Majumdar SR , Veugelers P , Johnson JA . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–8. [PubMed: 16443869]
241.
Saloranta C , Hershon K , Ball M , Dickinson S , Holmes D . Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab. 2002;87(9):4171–6. [PubMed: 12213867]
242.
Lester JW , Fernandes AW . Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. Int J Clin Pract. 2005;59(2):134–42. [PubMed: 15854187]
243.
Charbonnel B , Roden M , Urquhart R . et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia. 2005;48(3):553–60. [PubMed: 15739120]
244.
Belcher G , Lambert C , Goh KL , Edwards G , Valbuena M . Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract. 2004;58(9):833–7. [PubMed: 15529516]
245.
Khan M , Xu Y , Edwards G , Urquhart R , Mariz S . Effects of pioglitazone on the components of diabetic dyslipidaemia: Results of double-blind, multicenter, randomised studies. Int J Clin Pract. 2004;58(10):907–12. [PubMed: 15587767]
246.
Davidson J , Howlett H . New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis. 2004;4(4):273–7.
247.
Perez A , Khan M , Johnson T , Karunaratne M . Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res. 2004;1(1):44–50. [PubMed: 16305056]
248.
Roden M , Laakso M , Johns D . et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med. 2005;22(8):1101–6. [PubMed: 16026380]
249.
Belcher G , Schernthaner G . Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med. 2005;22(8):973–9. [PubMed: 16026360]
250.
Belcher G , Lambert C , Edwards G , Urquhart R , Matthews DR . Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2005;70(1):53–62. [PubMed: 16002175]
251.
Charbonnel B , Schernthaner G , Brunetti P . et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48(6):1093–104. [PubMed: 15889234]
252.
Ceriello A , Johns D , Widel M , Eckland DJ , Gilmore KJ , Tan MH . Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care. 2005;28(2):266–72. [PubMed: 15677777]
253.
Tan MH , Johns D , Glazer NB . Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50(7):1184–8. [PubMed: 15117857]
254.
Rajagopalan R , Perez A , Ye Z , Khan M , Murray FT . Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging. 2004;21(4):259–71. [PubMed: 15012171]
255.
Agrawal A , Sautter MC , Jones NP . Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther. 2003;25(11):2754–64. [PubMed: 14693302]
256.
Rendell MS , Glazer NB , Ye Z . Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications. 2003;17(4):211–7. [PubMed: 12810245]
257.
Kreider M , Heise M . Rosiglitazone in the management of older patients with type 2 diabetes mellitus. Int J Clin Pract. 2002;56(7):538–41. [PubMed: 12296617]
258.
Lebovitz HE , Kreider M , Freed MI . Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25(5):815–21. [PubMed: 11978674]
259.
Lee A , Morley JE . Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6(1):47–53. [PubMed: 9526970]
260.
Dornan TL , Heller SR , Peck GM , Tattersall RB . Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care. 1991;14(4):342–4. [PubMed: 2060439]
261.
Cefalu WT , Bell-Farrow A , Wang ZQ , McBride D , Dalgleish D , Terry JG . Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM. Drug Dev Res. 1998;44(1):1–7.
262.
Mari A , Gastaldelli A , Foley JE , Pratley RE , Ferrannini E . Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care. 2005;28(5):1132–8. [PubMed: 15855578]
263.
Leonhardt W , Hanefeld M , Fischer S , Schulze J , Spengler M . Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment. Arzneimittelforschung. 1991;41(7):735–8. [PubMed: 1772463]
264.
Karter AJ , Ahmed AT , Liu J , Moffet HH , Parker MM . Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005;22(8):986–93. [PMC free article: PMC3557913] [PubMed: 16026362]
265.
Abbasi AA , Kasmikha R , Sotingeanu DG . Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract. 2000;6(6):442–6. [PubMed: 11155215]
266.
Inzucchi SE . Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–72. [PubMed: 11790216]
267.
Chilcott J , Tappenden P , Jones ML , Wight JP . A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23(11):1792–823. discussion 1791. [PubMed: 11768834]
268.
Kahn BB , Flier JS . Obesity and insulin resistance. J Clin Invest. 2000;106(4):473–81. [PMC free article: PMC380258] [PubMed: 10953022]
269.
Lucas C , Johnson W , Hamilton MA . et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140(6):840–7. [PubMed: 11099986]
270.
Ness-Abramof R , Apovian CM . Drug-induced weight gain. Drugs Today (Barc). 2005;41(8):547–55. [PubMed: 16234878]
271.
Pijl H , Meinders AE . Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf. 1996;14(5):329–42. [PubMed: 8800628]
272.
Henry RR , Wallace P , Olefsky JM . Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35(9):990–8. [PubMed: 3527829]
273.
Gumbiner B , Polonsky KS , Beltz WF . et al. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1990;70(6):1594–602. [PubMed: 2189885]
274.
Kelley DE , Wing R , Buonocore C , Sturis J , Polonsky K , Fitzsimmons M . Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77(5):1287–93. [PubMed: 8077323]
275.
Bray GA , Bellanger T . Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine. 2006;29(1):109–17. [PubMed: 16622298]
276.
de Jongh RT, Ijzerman RG, Serne EH et al. Visceral and truncal subcutaneous adipose tissue are associated with impaired capillary recruitment in healthy individuals. J Clin Endocrinol Metab 2006. [PubMed: 17003093]
277.
Basu A , Jensen MD , McCann F , Mukhopadhyay D , Joyner MJ , Rizza RA . Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29(3):510–4. [PubMed: 16505497]
278.
Smith SR , De Jonge L , Volaufova J , Li Y , Xie H , Bray GA . Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 2005;54(1):24–32. [PubMed: 15562376]
279.
Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11(3):309–17. [PubMed: 8387089]
280.
Birkenhager WH , Staessen JA , Gasowski J , de Leeuw PW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol. 2000;13(3):232–7. [PubMed: 10928302]
281.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317(7160):703–13. [PMC free article: PMC28659] [PubMed: 9732337]
282.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24):3255–64. [PubMed: 2046107]
283.
Adler AI , Stratton IM , Neil HA . et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–9. [PMC free article: PMC27455] [PubMed: 10938049]
284.
Wang JG , Staessen JA , Gong L , Liu L . Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160(2):211–20. [PubMed: 10647760]
285.
Hansson L , Zanchetti A , Carruthers SG . et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–62. [PubMed: 9635947]
286.
Qayyum R , Adomaityte J . A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich). 2006;8(1):19–28. [PMC free article: PMC8109335] [PubMed: 16407685]
287.
Sarafidis PA , Lasaridis AN . Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens. 2006;19(6):646–53. [PubMed: 16733240]
288.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486–97. [PubMed: 11368702]
289.
Schrott HG , Bittner V , Vittinghoff E , Herrington DM , Hulley S . Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA. 1997;277(16):1281–6. [PubMed: 9109465]
290.
Allison TG , Squires RW , Johnson BD , Gau GT . Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. Mayo Clin Proc. 1999;74(5):466–73. [PubMed: 10319076]
291.
Lexchin J , Bero LA , Djulbegovic B , Clark O . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70. [PMC free article: PMC156458] [PubMed: 12775614]
292.
Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; (1):CD002967. [PubMed: 16437448]
293.
Norris, S, Carson, S, Roberts, C. Drug Class Review on Thiazolidinediones [Web Page]. May 2006; Available at http://www.ohsu.edu/drugeffectiveness/reports/documents/_TZDs%20Final%20Report.pdf. (Accessed September 2006).
294.
Damsbo P , Clauson P , Marbury TC , Windfeld K . A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care. 1999;22(5):789–94. [PubMed: 10332683]
295.
Brown JB , Pedula K , Barzilay J , Herson MK , Latare P . Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998;21(10):1659–63. [PubMed: 9773726]
296.
Misbin RI , Green L , Stadel BV , Gueriguian JL , Gubbi A , Fleming GA . Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338(4):265–6. [PubMed: 9441244]
297.
GlaxoSmithKline. Dear Healthcare Provider [Web Page]. January 2005; Available at http://www​.fda.gov/medwatch​/safety/2006/Avandia_DHCPletter​.pdf. (Accessed 18 October 2006).
298.
Actos. Actos (pioglitazone) prescribing information.
299.
GlaxoSmithKline Pharmaceuticals. Avandia (rosiglitazone maleate) prescribing information [Web Page]. June 2006; (Accessed 22 October 2006).
300.
Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004; (4):CD003418. [PMC free article: PMC9007040] [PubMed: 15495054]
301.
Chiquette E , Ramirez G , Defronzo R . A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164(19):2097–104. [PubMed: 15505122]
302.
Wulffele MG , Kooy A , de Zeeuw D , Stehouwer CD , Gansevoort RT . The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256(1):1–14. [PubMed: 15189360]
303.
Meriden T . Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004;26(2):177–90. [PubMed: 15038941]
304.
Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004; 8(13):iii, ix–x, 1–91. [PubMed: 15038907]
305.
Stades AM , Heikens JT , Erkelens DW , Holleman F , Hoekstra JB . Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255(2):179–87. [PubMed: 14746555]
306.
Salpeter SR , Greyber E , Pasternak GA , Salpeter EE . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163(21):2594–602. [PubMed: 14638559]
307.
van Wijk JP , de Koning EJ , Martens EP , Rabelink TJ . Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23(10):1744–9. [PubMed: 12907465]
308.
Salas M , Caro JJ . Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React Toxicol Rev. 2002;21(4):205–17. [PubMed: 12503254]
309.
Levien TL , Baker DE , Campbell RK , White JR Jr. Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother. 2001;35(11):1426–34. [PubMed: 11724096]
310.
Chilcott J , Wight J , Lloyd Jones M , Tappenden P . The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. Health Technol Assess. 2001;5(19):1–61. [PubMed: 11701097]
311.
Culy CR , Jarvis B . Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625–60. [PubMed: 11577798]
312.
Campbell LK , Baker DE , Campbell RK . Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother. 2000;34(11):1291–301. [PubMed: 11098345]
313.
Johansen K . Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care. 1999;22(1):33–7. [PubMed: 10333900]
314.
Chan NN , Brain HP , Feher MD . Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med. 1999;16(4):273–81. [PubMed: 10220200]
315.
McCartney MM , Gilbert FJ , Murchison LE , Pearson D , McHardy K , Murray AD . Metformin and contrast media—a dangerous combination? Clin Radiol. 1999;54(1):29–33. [PubMed: 9915507]
316.
Campbell RK . Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998;32(10):1044–52. [PubMed: 9793597]
317.
Campbell LK , White JR , Campbell RK . Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother. 1996;30(11):1255–62. [PubMed: 8913408]
318.
Melchior WR , Jaber LA . Metformin: an antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother. 1996;30(2):158–64. [PubMed: 8835050]
319.
Campbell IW , Howlett HC . Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev. 1995;11(Suppl 1):S57–62. [PubMed: 8529486]
320.
Campbell IW . Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl. 1985;15:105–11. [PubMed: 3935560]
321.
Vreven R , De Kock M . Metformin lactic acidosis and anaesthesia: Myth or reality? Acta Anaesthesiol. Belg. 2005;56(3):297–302. [PubMed: 16265833]
322.
Brunetti P , Pagano G , Turco C , Gori M , Perriello G . Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial. Diabetes Nutr Metab. 2004;17(6):350–7. [PubMed: 15887629]
323.
Cefalu WT , Schneider DJ , Carlson HE . et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care. 2002;25(12):2123–8. [PubMed: 12453948]
324.
Girnun GD , Smith WM , Drori S . et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A. 2002;99(21):13771–6. [PMC free article: PMC129773] [PubMed: 12370429]
325.
Evans JM , Donnelly LA , Emslie-Smith AM , Alessi DR , Morris AD . Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5. [PMC free article: PMC558205] [PubMed: 15849206]
326.
Rajagopalan R , Iyer S , Perez A . Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab. 2005;7(2):161–9. [PubMed: 15715889]
327.
Rajagopalan R , Rosenson RS , Fernandes AW , Khan M , Murray FT . Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther. 2004;26(9):1400–10. [PubMed: 15531002]
328.
Ko SH , Song KH , Ahn YB . et al. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism. 2003;52(6):731–4. [PubMed: 12800099]
329.
Garber AJ , Bruce S , Fiedorek FT . Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. Clin Ther. 2002;24(9):1401–13. [PubMed: 12380632]
330.
Rosenstock J , Shen SG , Gatlin MR , Foley JE . Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care. 2002;25(9):1529–33. [PubMed: 12196422]
331.
Deerochanawong C , Chandraprasert S , Suthijumroon A . et al. Glimepiride in type 2 diabetes mellitus Thai patients. J Med Assoc Thai. 2001;84(9):1221–8. [PubMed: 11800292]
332.
Emslie-Smith AM , Boyle DI , Evans JM , Sullivan F , Morris AD . Contraindications to metformin therapy in patients with Type 2 diabetes—a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18(6):483–8. [PubMed: 11472468]
333.
Tsumura K . Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract. 1995;28(Suppl):S147–9. [PubMed: 8529507]
334.
Menzies DG , Campbell IW , McBain A , Brown IR . Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules. Curr Med Res Opin. 1989;11(5):273–8. [PubMed: 2702849]
335.
Hermann LS , Nilsson B , Wettre S . Vitamin B12 status of patients treated with metformin: A cross-sectional cohort study. Br. J. Diabetes Vasc. Dis. 2004;4(6):401–6.
336.
Chalmers J , McBain AM , Brown IRF , Campbell IW . Metformin: Is its use contraindicated in the elderly? PRACT DIABETES. 1992;9(2):51–3.
337.
Profozic V , Resman Z , Cabrijan T . et al. Multicentric clinical research of gliclazide (Predian) carried out during a 12-month period in 10 centres of Croatia. DIABETOL CROAT. 1987;16(34):171–5.
Copyright Notice
Bookshelf ID: NBK43048
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (905K)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...